Martin D. Madaus - 18 May 2023 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Role
Director
Signature
/s/ Kimberly Brown (Attorney in Fact)
Issuer symbol
RGEN
Transactions as of
18 May 2023
Net transactions value
$0
Form type
4
Filing time
22 May 2023, 21:48:41 UTC
Previous filing
08 May 2023
Next filing
16 Jun 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGEN Common Stock Award $0 +686 +43% $0.000000 2,297 18 May 2023 Direct F1
holding RGEN Common Stock 11 18 May 2023 Spouse Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGEN Stock Option (Right to Buy) Award $0 +1,487 $0.000000 1,487 18 May 2023 Common Stock 1,487 $156.63 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Mr. Madaus was awarded 686 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 18, 2024, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.
F2 Award vests in full on the earlier of May 18, 2024, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.